VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed May 15, 2023. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 27
- 0 vs. Q1 2022
- Portfolio value
- $507.8M
- −$109.5M (−17.7%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| XENEXenon Pharmaceuticals Inc. | COM | 30,000 | $913.0K | 0.2% | +30,000 | New | History |
| RLYBRallybio Corp | COM | 268,532 | $2.03M | 0.4% | +268,532 | New | History |
| Affimed N VN01045108 | COM | 1,428,571 | $3.96M | 0.8% | 00.0% | Unchanged | – |
| ATYRaTYR PHARMA INC | COM NEW | 1,398,889 | $3.96M | 0.8% | 00.0% | Unchanged | History |
| ALTAltimmune, Inc. | COM NEW | 369,306 | $4.32M | 0.9% | −390,413−51.4% | Reduced | History |
| PRVBProvention Bio, Inc. | COM | 1,118,653 | $4.47M | 0.9% | 00.0% | Unchanged | History |
| LYRALyra Therapeutics, Inc. | COM | 924,170 | $5.22M | 1.0% | +924,170 | New | History |
| SVRASavara Inc | COM | 4,117,530 | $6.26M | 1.2% | +2,212,265+116.1% | Added | History |
| ANNXAnnexon, Inc. | COM | 1,928,477 | $7.27M | 1.4% | +1,928,477 | New | History |
| KDNYChinook Therapeutics, Inc. | COM | 489,618 | $8.56M | 1.7% | −794,203−61.9% | Reduced | History |
| TRVITrevi Therapeutics, Inc. | COM | 3,050,022 | $8.57M | 1.7% | +3,050,022 | New | History |
| JBIOJade Biosciences, Inc. | COM | 590,408 | $9.23M | 1.8% | +439,371+290.9% | Added | History |
| LIANYLianBio | SPONSORED ADS | 5,378,341 | $11.6M | 2.3% | 00.0% | Unchanged | History |
| AKUSAkouos, Inc. | COM | 2,667,119 | $12.5M | 2.5% | +2,667,119 | New | History |
| INZYInozyme Pharma, Inc. | COM | 2,709,987 | $12.9M | 2.5% | +2,709,987 | New | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 1,173,518 | $14.5M | 2.8% | −355,884−23.3% | Reduced | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 3,156,803 | $15.3M | 3.0% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 20,697,286 | $18.2M | 3.6% | +4,650,000+29.0% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,852,919 | $21.4M | 4.2% | 00.0% | Unchanged | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 865,116 | $23.3M | 4.6% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM | 5,997,657 | $27.7M | 5.5% | −867,419−12.6% | Reduced | History |
| GHRSGH Research PLC | ORDINARY SHARES | 3,185,573 | $31.8M | 6.3% | +1,134,513+55.3% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 4,038,117 | $36.4M | 7.2% | +2,949,300+270.9% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,711,102 | $41.5M | 8.2% | −283,895−14.2% | Reduced | History |
| RLMDRelmada Therapeutics, Inc. | COM | 2,270,072 | $43.1M | 8.5% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $63.7M | 12.5% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 7,132,079 | $69.0M | 13.6% | +2,637,228+58.7% | Added | History |
Sold out since Q1 2022 (7)
Positions held at the end of Q1 2022 that are gone from this filing.
| Security | Class | Shares in Q1 2022 | Value in Q1 2022 | % of portfolio in Q1 2022 | History |
|---|---|---|---|---|---|
| LONALeonaBio, Inc. | COM | 1,000,000 | $13.5M | 2.2% | History |
| EIGREiger BioPharmaceuticals, Inc. | COM | 1,469,767 | $12.2M | 2.0% | History |
| NUVLNuvalent, Inc. | COM | 803,951 | $11.2M | 1.8% | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,612,617 | $8.22M | 1.3% | History |
| SRRASierra Oncology, Inc. | COM NEW | 162,479 | $5.21M | 0.8% | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 411,361 | $3.69M | 0.6% | History |
| ATXSAstria Therapeutics, Inc. | COM | 538,999 | $3.62M | 0.6% | History |